⌕
Arbutus Biopharma · ABUS · Nasdaq
Tenet 49 · Mixed
Compare
$4.09+1.49%At closeTenet 49 · Mixed
$4.09+0.06 (+1.49%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Arbutus Biopharma (ABUS) Stock

Arbutus Biopharma (ABUS) closed at $4.09 on Nov 13, 2026; its Tenet Score is 49 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$4.09
Nov 13, 2026
Market cap
$627.0M
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
2.9×
price ÷ trailing EPS, Nov 13, 2026 close
Dividend yield
0.00%
reinvests all
52-week range
3.50 – 5.45
low → high
Tenet Score
49/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Arbutus Biopharma Corp scores 49/100. Mixed. Growth is the soft spot, trading at 3× earnings versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
49/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
62
Quality
52
Health
44
Growth
36

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityCHealthDGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
7.3×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
44.5×
price to fiscal 2025 sales
ROE
270%
TTM through Sep 30, 2026
Operating margin
−271.0%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
1.40
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 3y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcu…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 64 US ETFs · top wrappers by weightSee all ETFs holding ABUS →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Arbutus Biopharma in?

Arbutus Biopharma is in the Healthcare sector and the Drugs industry.

What is Arbutus Biopharma's Tenet Score?

Arbutus Biopharma's Tenet Score is 49 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.